138 related articles for article (PubMed ID: 11315254)
21. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.
Nekarda H; Schmitt M; Ulm K; Wenninger A; Vogelsang H; Becker K; Roder JD; Fink U; Siewert JR
Cancer Res; 1994 Jun; 54(11):2900-7. PubMed ID: 8187075
[TBL] [Abstract][Full Text] [Related]
22. [Genetic alterations in stomach cancer].
Tahara E; Yasui W; Yokozaki H
Nihon Geka Gakkai Zasshi; 1996 Apr; 97(4):252-6. PubMed ID: 8692139
[TBL] [Abstract][Full Text] [Related]
23. Expression and significance of IGF-2, PCNA, MMP-7, and α-actin in gastric carcinoma with Lauren classification.
Kuang RG; Wu HX; Hao GX; Wang JW; Zhou CJ
Turk J Gastroenterol; 2013; 24(2):99-108. PubMed ID: 23934455
[TBL] [Abstract][Full Text] [Related]
24. Expression of cadherin-catenin cell adhesion molecules, phosphorylated tyrosine residues and growth factor receptor-tyrosine kinases in gastric cancers.
Akimoto S; Ochiai A; Inomata M; Hirohashi S
Jpn J Cancer Res; 1998 Aug; 89(8):829-36. PubMed ID: 9765619
[TBL] [Abstract][Full Text] [Related]
25. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems.
Allgayer H; Babic R; Gruetzner KU; Tarabichi A; Schildberg FW; Heiss MM
J Clin Oncol; 2000 Jun; 18(11):2201-9. PubMed ID: 10829039
[TBL] [Abstract][Full Text] [Related]
26. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
27. Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer.
Mizutani T; Onda M; Tokunaga A; Yamanaka N; Sugisaki Y
Cancer; 1993 Oct; 72(7):2083-8. PubMed ID: 8397058
[TBL] [Abstract][Full Text] [Related]
28. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.
Nekarda H; Schlegel P; Schmitt M; Stark M; Mueller JD; Fink U; Siewert JR
Clin Cancer Res; 1998 Jul; 4(7):1755-63. PubMed ID: 9676852
[TBL] [Abstract][Full Text] [Related]
29. Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma.
Wu CW; Li AF; Chi CW; Chung WW; Liu TY; Lui WY; P'eng FK
Oncol Rep; 1998; 5(4):817-22. PubMed ID: 9625824
[TBL] [Abstract][Full Text] [Related]
30. E-cadherin and urokinase-type plasminogen activator tissue status in gastric carcinoma.
Yonemura Y; Nojima N; Kaji M; Fujimura T; Itoh H; Ninomiya I; Miyazaki I; Endo Y; Sasaki T
Cancer; 1995 Sep; 76(6):941-53. PubMed ID: 8625219
[TBL] [Abstract][Full Text] [Related]
31. Gene amplification of CCNE1, CCND1, and CDK6 in gastric cancers detected by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization.
Ooi A; Oyama T; Nakamura R; Tajiri R; Ikeda H; Fushida S; Dobashi Y
Hum Pathol; 2017 Mar; 61():58-67. PubMed ID: 27864121
[TBL] [Abstract][Full Text] [Related]
32. [Multistep stomach carcinogenesis].
Yokozaki H; Tahara E
Nihon Rinsho; 1996 Apr; 54(4):1066-71. PubMed ID: 8920675
[TBL] [Abstract][Full Text] [Related]
33. Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer.
Ascaño JJ; Frierson H; Moskaluk CA; Harper JC; Roviello F; Jackson CE; El-Rifai W; Vindigni C; Tosi P; Powell SM
Mod Pathol; 2001 Oct; 14(10):942-9. PubMed ID: 11598162
[TBL] [Abstract][Full Text] [Related]
34. Distinction of differentiated type early gastric carcinoma with gastric type mucin expression.
Koseki K; Takizawa T; Koike M; Ito M; Nihei Z; Sugihara K
Cancer; 2000 Aug; 89(4):724-32. PubMed ID: 10951333
[TBL] [Abstract][Full Text] [Related]
35. Alterations of APC, c-met, and p53 genes in tumor tissue and serum of patients with gastric cancers.
Wang JY; Hsieh JS; Chen CC; Tzou WS; Cheng TL; Chen FM; Huang TJ; Huang YS; Huang SY; Yang T; Lin SR
J Surg Res; 2004 Aug; 120(2):242-8. PubMed ID: 15234219
[TBL] [Abstract][Full Text] [Related]
36. INC280 inhibits Wnt/β-catenin and EMT signaling pathways and its induce apoptosis in diffuse gastric cancer positive for c-MET amplification.
Sohn SH; Kim B; Sul HJ; Kim YJ; Kim HS; Kim H; Seo JB; Koh Y; Zang DY
BMC Res Notes; 2019 Mar; 12(1):125. PubMed ID: 30871613
[TBL] [Abstract][Full Text] [Related]
37. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas.
Nakajima M; Sawada H; Yamada Y; Watanabe A; Tatsumi M; Yamashita J; Matsuda M; Sakaguchi T; Hirao T; Nakano H
Cancer; 1999 May; 85(9):1894-902. PubMed ID: 10223227
[TBL] [Abstract][Full Text] [Related]
38. Geno- and pheno-typic characterization in ten patients with double-primary gastric and colorectal adenocarcinomas.
Kim JC; Koo KH; Kim HC; Kim JS; Kang GH
Int J Colorectal Dis; 2004 Nov; 19(6):561-8. PubMed ID: 15083323
[TBL] [Abstract][Full Text] [Related]
39. Expression of urokinase-type plasminogen activator, its receptor, and its inhibitor in gastric adenocarcinoma tissues.
Hong SI; Park IC; Son YS; Lee SH; Kim BG; Lee JI; Lee TW; Kook YH; Min YI; Hong WS
J Korean Med Sci; 1996 Feb; 11(1):33-7. PubMed ID: 8703368
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of bcl-2 expression in gastric cancer.
Müller W; Schneiders A; Hommel G; Gabbert HE
Anticancer Res; 1998; 18(6B):4699-704. PubMed ID: 9891543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
